Participated · Equity · Jun 2026

Enventric develops vascular medical devices for cerebral infarction treatment, with approved products including the EvoGlide distal access catheter and the ULTRIVA stent retriever. The company reported cumulative revenue of about 6 billion won over the past four years and a compound annual growth rate of 52.9% over that period. Enventric is accelerating R&D and expanding manufacturing capacity following recent regulatory approvals. It is pursuing global market entry and has begun formal IPO preparations on KOSDAQ, appointing Kiwoom Securities as its underwriter. The recent 34.5 billion won pre-IPO equity raise broadens its institutional investor base and includes follow-on participation from several existing investors. Management has stated the capital will be used to bolster R&D, scale manufacturing, and support the company’s listing and international expansion efforts.

Participated · Series C · Mar 2026

MustBio develops next-generation immuno-oncology therapies using a multi-antibody platform called BICSTA and a tumor-selective immunocytokine platform called STARKINE. The company is advancing a portfolio of tri-specific fusion immuno-oncology candidates, with lead programs including MB5 (an IL-2–based therapeutic in clinical development) and MB7 (an IL-21–based program in R&D). Since its founding in 2021, MustBio has raised a total of 635억원 across prior rounds and the recent Series C. The firm has entered collaboration and licensing arrangements with Celltrion and was selected for JLABS Korea and the Seoul BioHub open innovation programs. Proceeds from the Series C are earmarked to accelerate MB5 clinical work, advance MB7 R&D, expand the pipeline, and support global business development and potential technology licensing. Management has stated plans to pursue additional tri-specific antibody R&D and broaden global partnerships.

Participated · Series A · Mar 2024

Testbank runs the digital-reference service '쏠브', which adapts paper reference books and problem workbooks for a digital learning environment. The product includes problem-solving‑optimized note features such as auto-graded PDFs and an automatic wrong-answer notebook. Since launch, 쏠브 attracted 10,000 organically acquired users within one year and achieved recommendation scores in the high 9s. The company began partnerships with major 수능 education players including Megastudy Education and Jinhaksa last year, and this year added collaborations with MegaMD, MegaLand and Ubion (operator of WowPass). Management plans to expand into the employment and professional certification market. CEO Choi Hyun-wook emphasized that 테스트뱅크 is addressing prerequisites for digital learning, including a question database and learning management systems. TestBank develops technology that transforms book-format textbook data into digital, interactive learning content using machine learning. Its platform implements features such as pen/annotation tools, an error-note system, and automatic grading to support effective tablet-based studying. The company plans to launch a digital reference-book platform called SOLVE and is negotiating copyrights with domestic reference-book publishers to distribute content digitally. TestBank has signed an MOU with Pagoda Education Group to build a digital reference-book service and learning management system. In November 2021 the company reached the finals of an AI championship and received the '창업진흥원장상' award. It was selected for the 2022 Youth Startup Academy and is preparing to enter the program. TestBank recently secured an initial seed investment from POSTECH Holdings to support its product development and rollout.

Participated · Series A · Jan 2024

Eloylab develops hyperspectral imaging–based deep learning AI solutions primarily used for foreign-object detection and quality control in food production lines. Its technology has been adopted by multiple food companies and is being further deployed with large food manufacturers. The company is also exploring adoption and partnerships in secondary batteries, pharmaceuticals, and recycling. Eloylab recently completed a Series A round (see deal notes) and its cumulative funding now stands at about ₩7.0 billion. SCI Evaluation Information assigned Eloylab a TI3 technology-credit rating, citing strong technical capability and future growth potential. The CEO stated the new funding will be used to optimize the hyperspectral AI solution and expand research capabilities to advance the company’s stated vision.

Participated · Series A · Jan 2024

Pion Electric is a venture founded in 2015 by Yoon Kwang‑hee and lab colleagues from Yonsei University that develops grid‑forming inverter control and operation technology. Its core product is a grid‑forming inverter that can autonomously form voltage and frequency, improving stability for power grids with high renewable penetration and reducing exposure to output curtailment. The company says installations of its inverter are placed lower on the power exchange’s curtailment priority, helping operators avoid losses from output restrictions. Pion Electric recently received a TI‑2 grade from Korea Evaluation Data’s investment technology evaluation, signaling top‑level technical capability. Following a new financing, the company has hired Lee Young‑gi as CFO to lead listing preparations and plans to select a lead manager and pursue a KOSDAQ IPO. The business narrative in the articles emphasizes addressing increasing grid instability caused by rapid growth in solar generation, especially in regions with high renewable shares like Jeju.